Brainomix vs Nicolab
Updated October 16, 2026
Stroke networks that want AI to help smaller hospitals decide on clot removal or transfer often compare Brainomix and Nicolab. Both spun out of European stroke research, but Brainomix reads more scan types and has the larger body of real-world evidence, while Nicolab focuses on sharing images and messages between hospitals in a network. American networks should weigh where each has published results.
Our analysts compared Brainomix and Nicolab on scan types, case sharing, real-world results, adoption, uses beyond stroke, and rollout, using the HIR review of each company and both vendors' sites. In the following sections, we compare the platforms, describe the network each fits, and list each company's recent news.
Brainomix vs Nicolab at a glance, October 2026
| What buyers weigh | Brainomix | Nicolab |
|---|---|---|
| Pricing model | Subscription quoted by Brainomix, usually by hospital or network, with national and regional contracts in Europe. | Subscription quoted by Nicolab, with network contracts for regional and national stroke programs. It is also offered through the Harrison.ai Open Platform, which Nicolab describes as zero-markup. |
| What drives cost | The number of hospitals, which scan types are analyzed, whether you add Vantage network analytics, and whether you add e-Lung. | Number of hospitals in the network, which StrokeViewer algorithms are used, and the number of Nicolab Assist users. |
| Scan types it reads | Non-contrast CT, CT angiography, CT perfusion, and MRI. Clear edge | StrokeViewer flags blocked large arteries and analyzes CT perfusion scans. |
| Sharing a case between hospitals | Sells Vantage network analytics as an option, and its main product reads the scan. | Nicolab Assist lets stroke teams at different hospitals see the same images and message each other from a phone or computer. Clear edge |
| Real-world results | A Lancet Digital Health study of more than 450,000 patients at 107 NHS England hospitals found clot-removal rates rose 100 percent at the 26 hospitals using it, compared with 63 percent at the others. Clear edge | Hospitals in Australia and Europe using it performed 28 percent more clot removals in patients transferred in the early window. |
| Hospitals using it | More than 300 hospitals in more than 20 countries, including national rollouts in Hungary and Wales in 2021. Clear edge | More than 200 hospitals by 2023, including the U.S. Department of Veterans Affairs. |
| Uses beyond stroke | Its e-Lung software measures lung fibrosis, which is scarring of the lungs, on CT and is cleared by the FDA. Clear edge | Built for stroke only. |
| Getting hospitals live | Scores 7.7, and it needs a network lead and baseline data to measure results against. Higher score | Scores 7.3, and every hospital in the network has to agree to share images. |
| Ways to buy | Subscription by hospital or network, with national and regional contracts in Europe. | Subscription by network, also sold through the Harrison.ai Open Platform, where hospitals pay Nicolab directly with no platform markup. |
| Time to full value | About 5 to 13 months | About 5 to 10 months |
| What you need first | Stroke network lead. | Network owner across hospitals. |
| Deal-breaker | No one leads the stroke network. | Nobody owns the network. |
| Pricing clarity score | 6.8 | 6.8 |
| HIR overall score | 7.8, Recommend. Higher score | 7.3, Recommend. |
| Best for | Regional and national stroke networks that want proof from large real-world studies. | Regional stroke networks, including remote video stroke consult programs, that need images and messages shared between hospitals. |
| Not a fit for | Hospitals that want a single vendor for every imaging AI use. | Large U.S. comprehensive stroke centers that want the platform with the most U.S. studies. |
Which fits which buyer
Ask whether reading scans or coordinating hospitals is your bigger gap.
Choose Brainomix if
- You want large real-world studies behind the product.
- You read CT, CT angiography, CT perfusion, and MRI.
- You may also want lung fibrosis measurement from the same vendor.
Choose Nicolab if
- Your network runs remote video stroke consults.
- Teams at different hospitals need to see the same images and message each other.
- You buy through public-sector contracts or a marketplace platform.
Verdict
Brainomix scores higher and suits networks that want the strongest evidence and broad scan support. Nicolab fits networks whose main problem is coordinating care between hospitals.
Neither is a single vendor for every imaging AI need.
Where the two tools are headed in 2027 and beyond
Brainomix: Brainomix extended its Series C financing to support American expansion on February 24, 2026, and presented positive Phase 2a lung fibrosis trial results with Endeavor on September 8, 2026.
Nicolab: Nicolab announced a partnership with Royal Philips on March 18, 2026.
Ask each for door-to-treatment results from a network your size.
Methodology
Each row comes from the HIR reviews of Brainomix and Nicolab, scored under the HIR method, and from each vendor's public pricing where it exists. Any published price for Brainomix or Nicolab was checked on that vendor's own site on October 16, 2026.
A green check marks a clear edge for Brainomix or Nicolab only where their review scores differ by at least 0.3 points or the two reviews show a plain difference. Rows with nothing published for either Brainomix or Nicolab are left out, and time to full value for each adds up the rollout stages in its review.
Sources
- HIR review of Brainomix and HIR review of Nicolab
- Brainomix website
- Nicolab website
- Brainomix Series C extension, February 24, 2026
- Brainomix and Endeavor Phase 2a results, September 8, 2026
- Philips partners with Nicolab, March 18, 2026